Abstract:We have developed a genetic "intrakine" strategy to inactivate the CC-chemokine receptor 5 (CCR-5), the principal coreceptor for macrophage (M)-tropic HIV-1 viruses (Yang et al., 1997). The inactivation of CCR-5 was achieved by targeting a modified CC-chemokine (RANTES) to the lumen of the endoplasmic reticulum (ER) to block the transport of the newly synthesized CCR-5. The transduced lymphocytes with the phenotypic CCR-5 knockout were shown to be resistant to M-tropic HIV-1 infection. This study illustrated the feasibility of the intrakine strategy to block HIV-1 infection. In our current study, the potential clinical application of the intrakine approach was further evaluated in human peripheral blood lymphocytes (PBLs), PBLs were transduced with the RANTES intrakine gene by using retroviral vectors with the truncated low-affinity human nerve growth factor receptor (Delta NGFR) marker, and then isolated by an anti-NGFR antibody/magnetic bead method. The surface expression of CCR-5 in the transduced lymphocytes was dramatically inhibited, as demonstrated by flow cytometric assays. The transduced PBLs were shown to resist various types of M-tropic HIV-1 virus infection. The cell viability, cell proliferation rates, and cell surface markers of the intrakine-transduced PBLs were shown to be comparable to those of control PBLs. The transduced PBLs were also found to respond to the stimulation of various CXC- and CC-chemokines, other than RANTES. The transduced PBLs responded to tetanus antigen stimulation by increasing IL-2 production and cell proliferation. In addition, a functionally defective mutant of RANTES that retains its binding activity to CCR-5, but loses its signaling ability, was used to generate a mutant RANTES intrakine. The primary lymphocytes transduced with the mutant RANTES intrakine were found to be resistant to M-tropic HIV-1 infection. From these results, we conclude that the primary human lymphocytes transduced with either the wild-type or functionally defective RANTES intrakine are resistant to M-tropic HIV-1 infection, and maintain their basic biological functions. This study, therefore, indicates the potential clinical application of the intrakine approach for HIV-1 gene therapy.

Structural and Functional Studies of the Potent Anti-Hiv Chemokine Variant P2-Rantes

Structure-Function Study and Anti-Hiv Activity of Synthetic Peptide Analogues Derived from Viral Chemokine Vmip-Ii

Preclinical Evaluation of Synthetic −2 RANTES As a Candidate Vaginal Microbicide to Target CCR5

Highly Potent Chimeric Inhibitors Targeting Two Steps of HIV Cell Entry

A Novel Synthetic Chemokine Containing D-Amino Acids That Binds To The Cxcr4 Receptor And Inhibits Hiv-1 Infection

CCR5 Antagonist TD-0680 Uses a Novel Mechanism for Enhanced Potency Against HIV-1 Entry, Cell-mediated Infection, and a Resistant Variant

Molecular binding mode of PF-232798, a clinical anti-HIV candidate, at chemokine receptor CCR5

A Novel Peptide Antagonist of CXCR4 Derived from the N-Terminus of Viral Chemokine Vmip-Ii

Anti-HIV type 1 activity of wild-type and functional defective RANTES intrakine in primary human lymphocytes.

Crystal Structure and Structural Mechanism of a Novel Anti-Human Immunodeficiency Virus Andd-Amino Acid-Containing Chemokine

Recent Progress in Small Molecule CCR5 Antagonists As Potential HIV-1 Entry Inhibitors

Structure-Based Design of 1-Heteroaryl-1,3-propanediamine Derivatives As a Novel Series of CC-Chemokine Receptor 5 Antagonists.

NMR Structures of Anti-Hiv D-peptides Derived from the N-terminus of Viral Chemokine Vmip-Ii.

N-terminal Proteolytic Processing by Cathepsin G Converts RANTES/CCL5 and Related Analogs into a Truncated 4-68 Variant

The effect of RANTES chemokine genetic variants on early HIV-1 plasma RNA among African American injection drug users.

A Novel Recombinant Chemokine Protein TAT-SDF-1/54-KDEL for Blocking CXCR4: Bioinformatics Analysis and Prokaryotic Expression (CCR5P.263)

Exploring the Stereochemistry of CXCR4-peptide Recognition and Inhibiting HIV-1 Entry with D-peptides Derived from Chemokines.

Potent and Broad Inhibition of HIV-1 by a Peptide from the Gp41 Heptad Repeat-2 Domain Conjugated to the CXCR4 Amino Terminus

2,4,5-Trisubstituted Pyrimidines as Potent HIV-1 NNRTIs: Rational Design, Synthesis, Activity Evaluation, and Crystallographic Studies

Interaction of the CC-Chemokine RANTES with Glycosaminoglycans Activates a p44/p42 Mitogen-Activated Protein Kinase-Dependent Signaling Pathway and Enhances Human Immunodeficiency Virus Type 1 Infectivity

Discovery of Novel Amino Acids (Analogues)-Substituted Thiophene[3,2- d]pyrimidine Derivatives as Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: Design, Synthesis, and Biological Evaluation